SHANGHAI, March 22, 2019 /PRNewswire/ — Exyte, the global leader in the design, engineering and construction of high-tech facilities, plants and factories, showcases its Smart Fab design concept at Semicon China 2019 in Shanghai from 20 March to 22 March.

Frank Lorenzetto, Managing Director of Exyte China, said: “The Smart Fab concept is an evolution beyond today’s typical approach of the optimization of CAPEX, speed and quality during design and construction. Exyte has focused on this transition and the development of solid expertise in digitalization. As the industry leader, we are dedicated to providing clients with an outstanding Fab in line with future trends. China is one of the most significant markets for us with huge potential for adoption and implementation of the Smart Fab concept.”

The Smart Fab concept utilizes developments in IoT technology, interconnected IT systems and automated analytics of the Big Data available in a semiconductor wafer fab. “Smart Fabs will be a key technology in the semiconductor industry to face the challenges of optimized capital expenditure (CAPEX), reduced operational expenditure (OPEX), as well as improved service from the Supply Chain”, John Zhang, Vice President Regional Business Unit Advanced Technological Facilities for Asia-Pacific explained.

The Digital Facilities Twin in the IoT Platform combines real time facility data with manufacturing data.

The Digital Facilities Twin is a core element of the Smart Fab concept consisting of a virtual digital model of the buildings and all facility systems. It is developed and maintained during design, construction and operation of a Fab. This transparent, digitalized platform consists of an advanced Building Integration Model (BIM) and incorporates real-time data from the core Facility Monitoring and Control System (FMCS) module, additional IoT sensors, as well as advanced data analytics. The Digital Twin also communicates with other systems including the Manufacturing Execution System (MES) and Enterprise Resource Planning (ERP) system.

With progressive implementation of the Smart Fab concept, Exyte’s clients will meet enhanced quality and safety standards and improve operational excellence through cost-efficient and reliable project implementation. This transparent and real-time information will also enable optimized system sustainability and increased energy efficiency throughout the fab’s Life Cycle.

Exyte has grown in China for over 24 years, with more than 300 projects implemented, and has built a strong trusted relationship with its clients and the supply chain. Being the only global company serving the Semiconductor and Life Sciences markets to hold a Grade A General Contractor License in China, the company is enabled to design and build facilities of all scale and sophistication.

To learn more about Smart Fab, visit Exyte at booth #1022 in Hall N1 at the Shanghai New International Expo Center.

About Exyte

Exyte is a global leader in design, engineering and construction delivering high-tech facilities, plants and factories. With a history of more than 100 years, the company has developed a special expertise in controlled and regulated environments. It serves the most technically demanding clients in growth markets such as semiconductors, life sciences, and data center across the full spectrum of services from consulting and design to managing turnkey solutions. Operating in more than 20 countries, Exyte is uniquely positioned to support clients locally and globally. In 2017, Exyte generated sales of 2.4 billion euros, up from 2.1 billion euros in 2016 on a like-for-like basis, with over 4,800 highly experienced and motivated employees (by the end of the year 2017). Exyte emerged from a regrouping of the M+W Group in 2018. Exyte is a member of the Stumpf Group. For further information about the company please see our website: www.exyte.net 

About Semicon China

Semicon China is the world’s fastest-growing trade fair, providing a platform to connect top tier manufacturers in the semiconductor industry with the most qualified audience of industry professionals in China.

Photo – https://photos.prnasia.com/prnh/20190321/2410571-1

BEIJING, March 21, 2019 /PRNewswire/ — The ceremony of “Village Warming with Blossom — Funding Presentation Ceremony on Countryside Poverty Alleviation” was held in Beijing. A total of 400 poverty alleviation pioneers from rural areas (100 each from the groups of poverty alleviation representatives, village doctors, village school principals, and village teachers) were recognized as the “Leading Persons in Poverty Alleviation and Support”, and each of them will receive poverty alleviation fund of RMB 10,000 provided by Ping An.

Equipping “Good Village Doctors” with AI technology

The purpose of this funding presentation ceremony is to implement the spirit of the speech of General Secretary of the Communist Party of China Xi Jinping, which said we should “start poverty alleviation with those with ambitions” and “support education in order for poverty alleviation”. The event is to recognize the pioneers in poverty alleviation from rural areas, in order to inspire more people to contribute to the poverty alleviation and development. The event was jointly established and hosted by the People’s Daily National Party Media Information Public Platform, China Soong Ching Ling Foundation and China Ping An. Jing Dunquan, Vice Chairman of the Soong Ching Ling Foundation of China, Xie Guoming, former Deputy Editor-in-Chief of the People’s Daily, and Sun Jianyi, Senior Vice Chairman of China Ping An Group, attended the funding presentation ceremony.

As the main force of health enhancement and poverty alleviation, village doctors are playing an important role in preventing poverty due to illness, returning to poverty due to illness, and safeguarding the health of villagers. Their task is arduous with tremendous responsibility. According to introduction, the event selected 100 “Good Village Doctors” from 15 provinces, municipalities and autonomous regions in Xinjiang, Inner Mongolia, Guangxi and etc. They all are highly praised by the villagers with their noble medical ethics, good service and superb medical techniques.

At the event, Zhu Hongqun, one of the “Good Village Doctors” from Cangzhou City of Jiangxi Province, said that the villagers in his area have been eager to have better medical conditions and services. He hopes to get further learning and training opportunities to provide more medical care services for the villagers. In October 2018, he received the professional training by the team under the “Village Doctor” program of China Ping An. Now he has learned to use the App developed specially for village doctors by Ping An Good Doctor, and he can interpret the health test reports, and utilise the healthcare instruments, including health testing all-in-one machine and medical camera all-in-one machine.

As an important part of the “Three-village Project” of Ping An Group, the “Village Doctor” program was jointly initiated by Ping An Healthcare and Technology Company Limited (“Ping An Good Doctor“, or the “Company”; stock code: 01833.HK) in conjunction with other China Ping An subsidiaries. Through consolidating national’s high-quality doctor resources and the donation of advanced medical and health equipment, the program helps village doctors to transform from the traditional “barefoot doctors” into the “village health gatekeepers” with general medical service capabilities.

In 2018, the “Village Doctor” program provided professional training for more than 5,000 village doctors in Guangxi, Jiangxi, Inner Mongolia and other regions. Supported by Ping An Good Doctor’s mobile medical platform and AI technology, the village doctors were assisted to provide more scientific and quality medical and health services for local villagers. It is estimated that by the end of 2019, the “Village Doctor” program will help upgrade 1,000 village clinics nationwide, empower more than 10,000 village doctors, and provide health check-ups and medical consultation services to more than 100,000 villagers.

According to Ping An Good Doctor, through the application of the world’s leading mobile medical and AI technology, the Company is transferring high-quality doctor resources, medical equipment and pharmaceutical resources to poor rural areas, and thus improving comprehensively the professional competence and service level of the village doctors. Currently, with its in-house medical team of 1196 members and over 5,000 external doctors, Ping An Good Doctor has been able to assist village doctors to provide online counseling, referral, registration, hospitalization, and second consultation advice to the villagers. The AI-assisted medical consultation system developed by Ping An Good Doctor can also assist the village doctors to automatically generate structured case information, thus be able to effectively standardize the consultation route, avoid omission of effective information, and improve the efficiency and accuracy of the consultation. According to statistics, Ping An Good Doctor’s AI-assisted medical consultation system has collected nearly 410 million consultation data, covering over 3,000 diseases.

About Ping An Healthcare and Technology Company Limited (01833.HK)

Ping An Good Doctor is the leading one-stop healthcare ecosystem platform in China. By combining “mobile health + AI technology”, the Company strives to provide every family with a family doctor, every person with an e-health profile and everyone with a healthcare management plan. Ping An Good Doctor has established a comprehensive, one-stop healthcare ecosystem covering family doctor services, consumer healthcare services, a health mall as well as health management and wellness interaction.

As of the end of December 2018, there were 265 million registered users and the Company’s MAU reached 54.7 million. Ping An Good Doctor is today the largest mobile medical application in China in terms of user scale. Ping An Good Doctor employs more than a thousand medical personnel (Assistant Supervisor Level or above from Class III Grade A Hospitals) in its in-house medical team and contracts with 5,203 renowned external doctors. This in-house medical team, empowered by our proprietary AI technology, provides users with 24 x 7 online consultation services. In our offline partnership network, Ping An Good Doctor collaborates with over 3,000 hospitals (including more than 1,200 Class III Grade A hospitals) to provide services such as hospital referral, appointment and inpatient arrangements.

Ping An Good Doctor also partners with more than 2,000 healthcare institutions, including physical examination centers, dental clinics, cosmetic surgery institutions and more than 15,000 pharmacy outlets, to provide relevant health and wellness services to our users. By integrating our AI-empowered medical team, external doctors and offline network, Ping An Good Doctor has established a closed-loop healthcare ecosystem which enables our users to enjoy online consultations and online drug purchases, as well as online consultations and offline follow-up treatment, thereby providing convenient, high-quality and efficient family doctor services.

In April 2015, the App “Ping An Good Doctor” was officially launched. In May 2016, the Company completed an A round financing and raised US$500 million. In December 2017, the Company completed the pre-IPO financing from Softbank Vision Fund, during which it raised US$400 million. On 4 May 2018, Ping An Good Doctor became the No.1 listed internet health-tech company in the world when it joined the Hong Kong Stock Exchange, stock code 1833.HK. Our IPO cornerstone investors include Blackrock, Capital Group, GIC, Canada Pension Plan Investment Board, Khazanah Nasional Berhad, Swiss Re and CP Group.

Photo – https://photos.prnasia.com/prnh/20190321/2410419-1

– Molsheim, France center supports pharmaceutical and biotechnology customers from pre-clinical through full-scale production in non-GMP environment

– Hands-on customer access to Merck’s Life Science product portfolio and technical expertise

– Manufacturing simulations encompass end-to-end process development

DARMSTADT, Germany, March 20, 2019 /PRNewswire/ — Merck, a leading science and technology company, today officially opened its new M Lab™ Collaboration Center in Molsheim, France. The center is Merck’s first in Europe and ninth worldwide, providing biopharmaceutical manufacturers with a shared, exploratory environment where they can closely collaborate with Merck scientists and engineers to solve their toughest challenges and accelerate development and production of new therapies.

Merck’s latest customer collaboration center in Molsheim, France, is expected to accelerate the growth of the local biopharmaceutical industry

“With the rapidly growing biopharma industry in Europe and demand for cost-effective therapies worldwide, customers will benefit from our expertise to develop processes for manufacturing drugs faster, safer and more effectively,” said Udit Batra, member of the Merck Executive Board and CEO, Life Science, in Molsheim today. “Our investment here will accelerate the future growth of EMEA’s biopharmaceutical industry.”

Merck’s newest M Lab™ Collaboration Center, which offers 4,000 square meters of space, represents a significant investment in the region. The €10 million center provides customers in Europe, the Middle East and Africa with a fully equipped, non-GMP pilot and bench scale lab and meeting center where they can work alongside Merck experts to solve their most pressing processing development challenges without impacting their production line.

The center in Molsheim is the latest in Merck’s network of centers around the world. Other M Lab™ Collaboration Centers are located in the United States, Brazil, China, South Korea, Singapore, Japan, India (where there are two labs).

Merck’s customers collaborate with the company’s technical experts, exploring new ways to increase productivity, improve processes and mitigate risks. The pilot and bench scale labs are in a space that simulates a real production environment across their process. Customers operate real equipment, evaluate their processes and can also take hands-on bioprocessing training courses, educating them on best practices and new approaches to develop, optimize and scale-up processes as well as simplify global technology transfer.

Follow Merck on Twitter @Merckgroup, on Facebook @merckgroup and on LinkedIn.

All Merck news are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2018, Merck generated sales of €14.8 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

Photo – https://mma.prnewswire.com/media/837208/Merck_M_Lab_Molsheim.jpg

New report from Clarivate Analytics identifies seven new drugs predicted to achieve annual sales of >$1 billion by 2023 

Game-changing therapies addressing immune-related and genetic disorders target under-served patient populations

PHILADELPHIA, March 20, 2019 /PRNewswire/ — Clarivate Analytics, a global leader in providing trusted insights and analytics to accelerate the pace of innovation, announced today the launch of its annual “Cortellis Drugs to Watch” report. The analysis identified seven new drugs forecasted to achieve annual sales of $1 billion or more (i.e., blockbuster status) by 2023 using data and analytics from Cortellis, the company’s suite of life science intelligence solutions. Additionally, the report highlights the impact of strategies and incentives put in place by global regulatory bodies to encourage the focus of drug development on niche markets and unmet medical needs.

The drugs forecasted to launch in 2019 are described in the Appendix below and dominated by immune-related and genetic disorders including: spinal muscular atrophy (SMA), rheumatoid arthritis (RA), paroxysmal nocturnal hemoglobinuria (PNH), and peanut allergy. This indicates a shift toward blockbuster-potential drugs targeting niche patient populations, buoyed by strong collaborations between big and specialty pharma companies to develop these therapies. Analysis also suggests the drugs highlighted in the report face a variety of market scenarios ranging from a first in class therapy with no competitors (AR-101 for peanut allergy), to having a single strong opponent (Zolgensma for SMA), to launching into a crowded market (Upadacitinib for RA), with each strategy having its own strengths and weaknesses. For the full list of drugs and their sales projections, please see the link provided below.

“This year’s Drug to Watch report demonstrates the impact of regulators’ incentives, including accelerated reviews and tax breaks, on drug development that targets rare diseases,” explained Mukhtar Ahmed, President of Life Sciences at Clarivate Analytics. “It’s extremely encouraging to see how these incentives, along with discovery breakthroughs and new R&D approaches, are positively impacting patients in under-served populations.  What’s more, these novel treatments demonstrate the power of collaboration across the industry, which ultimately accelerates innovation.”

Projections in the Cortellis Drugs to Watch 2019 report were determined using data and analytics in Cortellis, which curates the broadest and deepest sources of intelligence, including 70,000+ pipeline products, 325,000+ clinical trials, 91,000+ deals, and 165,000 company profiles. For the first time, Cortellis Drugs to Watch forecasts include insights from Cortellis Analytics – Drug Timeline & Success Rates (DTSR), a predictive analytics tool that improves the accuracy of pipeline forecasts vs. traditional methods by 25%.

The full report is available at: https://clarivate.com/drugstowatch2019  

Join the conversation on Twitter: @Cortellis | #blockbusterdrugs2019

About the Cortellis Drugs to Watch 2019 Report
Data and analysis featured in this report were derived using Cortellis, the suite of life science intelligence solutions from Clarivate Analytics. This includes Cortellis Competitive Intelligence, Cortellis Deals Intelligence, Cortellis Regulatory Intelligence, Cortellis Clinical Trials Intelligence and Cortellis Analytics – Drug Timeline & Success Rates, a patent-pending tool that applies machine learning to forecast the timeline and probability of success across all stages of drug development.

About Cortellis
Cortellis gives life to science by unlocking the hidden insights in data. As an industry-leading solution, Cortellis curates broad and deep sources of intelligence to enable precise, actionable answers to specific questions across the R&D lifecycle — from discovery and clinical development through regulatory submission and commercialization. By supporting data-driven decisions, Cortellis helps pharmaceutical companies, biotech and medical device/diagnostic firms accelerate innovation.

For more information, visit www.clarivate.com/products/cortellis/.  

Clarivate Analytics
Clarivate Analytics is a global leader in providing trusted insights and analytics to accelerate the pace of innovation. Building on a heritage going back more than a century and a half, we have built some of the most trusted brands across the innovation lifecycle, including the Web of Science, Cortellis, Derwent, CompuMark, MarkMonitor and Techstreet. Today, Clarivate Analytics is a new and independent company on a bold entrepreneurial mission, to help our clients radically reduce the time from new ideas to life-changing innovations.

For more information, please visit www.clarivate.com.

Forward-Looking Statements
This press release and oral statements made with respect to information contained in this release may contain forward-looking statements regarding Clarivate Analytics. Forward-looking statements provide Clarivate Analytics’ current expectations or forecasts of future events and may include statements regarding anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of Clarivate Analytics’ control that may cause actual results to differ materially. Clarivate Analytics undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise.

Media Contact
Jessica Stanek
e: media.enquiries@clarivate.com

Appendix

Table: Analysis of 7 new drugs forecast to enter the market in 2019 and achieve blockbuster sales of over $1 billion by 2023
Data was obtained from the Cortellis Competitive Intelligence database as of March 05, 2019. Forecasts are in U.S.$ million(M) and billion (B).  *=immune-related disease. ∆=genetic disorder. †=Breakthrough Therapy designation. ‡=Fast Track designation. |=Orphan Drug designation. §=Priority Review. ‡‡=first-in-class.

Logo – https://mma.prnewswire.com/media/455613/clarivate_logo_for_press_release_Logo.jpg  

BEIJING, March 19, 2019 /PRNewswire/ — Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a leading specialty hospital management solutions provider and an operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced three new appointments to the management team.

Concord Medical’s board of directors has appointed, effective immediately:

• Mr. Yaw Kong Yap as the President of the Company. Mr. Yap will continue to serve as Concord Medical’s Chief Financial Officer;
• Ms. Xiao Fu as the Chief Operating Officer; and
• Dr. Matthew D. Callister as the Chief Medical Officer.

Mr. Yap previously served as a Senior Vice President of the Company from 2008 to July 2014 and has been serving as the Company’s Chief Financial Officer since then. He served as a director and the financial controller of the Company from 2008 to 2011, the Chief Financial Officer of China Medstar in 2005 and the Chief Executive Officer of Advanced Produce Centre Development Pte, Ltd. in 2003. Mr. Yap graduated from the Indiana University of Pennsylvania in the United States with a bachelor’s degree in 1990. Mr. Yap is a Certified Public Accountant in the United States.

Ms. Xiao Fu has served as a Senior Vice President of the Company since July 2009. Ms. Xiao Fu joined China Medstar in 1997 and served as its Senior Vice President prior to Concord Medical’s acquisition of China Medstar. Prior to joining China Medstar, Ms. Xiao Fu served as a Sales Supervisor of Rhone-Poulenc Rorer from 1995 to December 1997. Ms. Xiao Fu graduated from the Shanghai Second Military Medical University in 1986, majoring in Healthcare.

Dr. Matthew D. Callister joined Concord Medical in March 2019. Prior to joining Concord Medical, Dr. Callister served as the Senior Physician Executive of Banner MD Anderson Cancer Center and Service Line in 2014, the Division Chief of Radiation Oncology at Banner MD Anderson Cancer Center in 2011 and a Consultant at the Department of Radiation Oncology of Mayo Clinic Arizona in 2004. Dr. Callister has been an Adjunct Associate Professor of Radiation Oncology at the UT-MD Anderson Cancer Center from 2011 to present. Dr. Callister received a Doctor of Medicine degree from the Duke University School of Medicine in 1997.

“We are very pleased to appoint Mr. Yaw Kong Yap as Concord Medical’s President, Ms. Xiao Fu as our Chief Operating Officer and Dr. Matthew D. Callister as our Chief Medical Officer,” said Dr. Jianyu Yang, Chairman and CEO of Concord Medical. “Each brings a wealth of professional leadership, academic excellence and business experience to Concord Medical. We look forward to working closely with them to execute our growth initiatives and create added value for our shareholders.”

About Concord Medical

Concord Medical Services Holdings Limited is a leading specialty hospital management solutions provider and an operator of the largest network of radiotherapy and diagnostic imaging centers in China. As of June 30, 2018, the Company operated a network of 30 centers with 21 hospital partners that spanned 21 cities and 14 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, the Company provides radiotherapy and diagnostic imaging equipment to and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients. For more information, please see http://ir.ccm.cn.

View original content:http://www.prnewswire.com/news-releases/concord-medical-announces-new-appointments-to-management-team-300814634.html

– License and Collaboration Agreement was signed between OliX and Théa for OLX301A program, a novel treatment for dry and wet age-related macular degeneration.
– OliX to receive an upfront payment of 2 million euro, and eligible to receive milestones, plus royalty for the development and commercialization in Europe, Middle East and Africa.
– OliX continues to hold the rights of OLX301A program for US and Asia.

SUWON, South Korea, March 18, 2019 /PRNewswire/ — 

OliX Pharmaceuticals, Inc. (Kosdaq: 226950), a leading developer of RNAi therapeutics, has today announced that it has signed a license and collaboration agreement with Théa Open Innovation, part of the Laboratoires Théa S.A.S (“Théa”) which is the leading French independent pharmaceutical company in Europe dedicated to ophthalmology, to develop and commercialize OLX301A.

Under the agreement, OliX receives a non-refundable and non-creditable upfront payment of 2 million euro and is eligible to receive milestone payments upon achievement of clinical milestones, plus royalty for the development and commercialization.

Dong-ki Lee, the founder and CEO of OliX, stated, “OliX’s cp-asiRNA platform technology is an RNAi platform optimal for the development of ocular therapeutics, which can circumvent potential side effects arising from the existing siRNA technology. The collaboration with Théa proves that OliX’s ophthalmology RNAi platform has been recognized in global pharmaceutical market, and we will continue to expand pipelines for eye diseases.”

Théa has been granted licensing rights for OLX301A program in EU countries, Middle East and Africa. OliX continues to hold the rights of OLX301A program for US and Asia.

Age-related macular degeneration diagnosed as either dry or wet is deterioration of the retina and deeper layers of the eye that can lead to a loss of eye sight. While effective therapies for wet AMD exist, the treatment burden may lead to less than optimal vision outcomes for many patients over time and no cure for dry AMD has been developed yet. OliX’s OLX301A program is a first in class treatment which cure both wet and dry AMD and is expected to be registered for FDA approval of IND for phase 1 clinical trial.

About Age-Related Macular degeneration (AMD)

• Occurs when the small central portion of the retina, known as the macula, deteriorates
• The leading cause of severe vision loss in people over age 60 in developed countries
• Two types: wet AMD (10%) & dry AMD (90%)
• In USA, 175 million patients affected by AMD in 2014 (Source: All about vision, Understanding AMD 2014)
• Global wet AMD market: $ 7.65B in 2015
• By 2025, expected dry AMD market: $ 6.58B (Source: Visiongain 2016)
• 98% of wet AMD patients were reported the onset of dry AMD in seven years
  (Source: Ophthalmology. 2012 Jul;119(7):1388-98., Ophthalmology. 2013 Nov;120(11):2292-9)
• Unmet medical needs for the development of a drug that can treat both wet and dry AMD exist
• Expected to grow to approx. about 11.6 B by 2026
  (Source: Global Data 2018, 7 major countries)

Thea Open Innovation, part of the Laboratoires THEA S.A.S

Laboratoires THEA S.A.S is a pharmaceutical industry specialized in ophthalmology. The group is the leader in several therapeutic classes as well as in the field of preservative-free eye drops. Laboratoires Théa is an innovative company dedicated to developing high-quality products that support ophthalmic care and eye health across more than 70 countries.

Learn more: https://www.laboratoires-thea.com/en

OliX Pharmaceuticals, Inc.

OliX is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The company is currently developing novel therapeutic programs for treatment of various diseases with high unmet medical needs, including hypertrophic scar, dry & wet age-related macular degeneration (AMD), subretinal fibrosis, and idiopathic pulmonary fibrosis (IPF).

Learn more: http://www.olixpharma.com/main/main.php

Contact:
OliX Pharmaceuticlas, Inc.
JOHN YOHAN LEE, Communication
yohani@olixpharma.com  

View original content to download multimedia:http://www.prnewswire.com/news-releases/thea-and-olix-announce-collaboration-to-develop-rnai-therapies-for-the-treatment-of-amd-300813709.html

Source: OliX Pharmaceuticals, Inc.

• Profit Attributable To Shareholders Increased 31.9% to HK$3,655 Million
• Innovative Drug Business Continued to Deliver Strong Growth
• R&D Deployment Further Improved

HONG KONG, March 18, 2019 /PRNewswire/ — CSPC Pharmaceutical Group Limited (HKEx: 01093) (“CSPC Pharmaceutical” or the “Group”), a leading pharmaceutical company in China, is pleased to announce its annual results for the year ended 31 December 2018 (the “Year”). For the Year, the Group recorded a turnover of approximately HK$21,029 million, representing an increase of 36.0% year-on-year. Profit attributable to shareholders was approximately HK$3,655 million, up 31.9% year-on-year. Basic earnings per share were HK58.55 cents. The Board of Directors (“The Board”) has proposed to declare the payment of a final dividend of HK18 cents per share.

During the Year, the gradual deepening of healthcare reform and full implementation of the new reimbursement drug list have provided the Group’s innovative drug products with increased room for market expansion. The Group swiftly expanded the dedicated sales force, strengthened academic-based promotion and accelerated market development in major cities and hospitals. Moreover, the Group penetrated into county-level hospitals and community medical institutions for end-user market development. With these efforts, innovative drug products continued the strong growth and achieved sales of HK$10,344 million in 2018, representing a 57.2% growth year-on-year. In particular, the sales of oncology drug portfolio increased by 123.3%, becoming a new major growth driver.

In respect of common generic drug business, the Group continued with the strategy of enhancing its sales mix by strengthening the promotion of non-antibiotic drugs and expanding the product line of oral formulation for chronic diseases. Furthermore, the Group actively pushed forward with the quality and efficacy consistency evaluation of generic drugs. During the Year, sales of common generic drug products maintained a satisfactory growth in general, with sales of HK$6,209 million, representing a 29.6% growth.

As to bulk drug business, the restraint on market supply of vitamin C due to pressure from environmental protection provided opportunities for large-scale vitamin C manufacturers, enabling this business to achieve a satisfactory performance during the Year. Caffeine business recorded a steady performance thanks to a stable operating environment.

In terms of research and development, the Group continued to increase its investment in the research and development of products during the Year. Currently there are more than 300 projects in the pipeline, primarily focusing on the therapeutic areas of cardio-cerebrovascular diseases, metabolic diseases (such as diabetes), oncology, psychiatry and neurology, as well as anti-infection. Among these product candidates, there are 30 macromolecule biologics, 40 new small molecule drugs and 55 Class 3 new drugs (classified as Class 3 or 4 under the new system).

Currently, there are 10 and 2 small molecule new drugs under clinical trials in China and the United States respectively; 7 new macromolecule drugs (including “anti-CD20 monoclonal antibody for injection”, “anti-EGFR monoclonal antibody for injection”, “anti-RANKL monoclonal antibody for injection” and 2 bispecific antibodies) under clinical trials in China; and 4 new preparations (including “Mitoxantrone liposome for injection”) under clinical trial as well.

In addition, 26 drugs are currently pending production approval, including “dronedarone hydrochloride tablets”, “clopidogrel hydrogen sulfate tablets”, “amphotericin B cholesterol sulfate complex for injection” (new preparation), “pramexole hydrochloride tablets” and “sacubitril / valsartan sodium tablets”; and 6 drugs are currently pending U.S. ANDA approval. Moreover, “mitoxantrone hydrochloride liposome for injection”, antibody-drug conjugate “DP303c”, “butylphthalide soft capsule” (indication: ALS) and “ALMB-0166” have been granted the orphan drug designation in U.S..

The Group continued to increase its investment in the pipeline of biologics and small molecule innovative drugs. Apart from in-house research and development, the Group has also been proactively seeking for external cooperation and acquisition opportunities. Multiple cooperation or acquisition projects have been made recently or during the Year in order to improve the pipeline layout. The future acquisition efforts will mainly focus on drugs of new small molecule and macromolecule which are close to product approval and commercial launch so as to supplement the pipeline of product launch in the next few years, and fully leverage the Group’s strong marketing and market development capabilities to achieve rapid sales growth of new products.

About CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group Limited is a leading pharmaceutical group in China. The Company has been listed on the Main Board of the Hong Kong Stock Exchange since 1994 and has become a constituent stock of Hang Sang Index since June 2018. CSPC Pharmaceutical is a leading player of innovative and common generic drugs in China. Major products include “NBP”, “Duomeisu”, “Jinyouli” and “Keaili”. It is also a major manufacturer of bulk drugs, principal products including vitamin C, caffeine and antibiotics. The production facilities of CSPC Pharmaceutical are mainly located in Shijiazhuang City, Hebei Province, China. For more information, please visit its website at http://www.cspc.com.hk.

Logo – https://photos.prnasia.com/prnh/20190315/2404689-1LOGO

NORTH BRUNSWICK, N.J., March 15, 2019 /PRNewswire/ — Adlai Nortye Ltd. (“Adlai Nortye”), a global clinical-stage biopharmaceutical company today released the animal model data of Buparlisib (AN2025) at the 7th ICHNO, the International Conference on Innovative Approaches in Head & Neck Oncology. The data suggests AN2025 could potentially be a treatment option for anti-PD-1 antibodies refractory tumors.

Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers in the world. Although anti-PD-1 antibodies have been approved by the FDA and EMA for the treatment of relapsed, refractory HNSCC, the response rates following nivolumab and pembrolizumab are both lower than 20%. Treatment of anti-PD-1 antibodies refractory patients remains to be an unmet medical need. 

Buparlisib is an oral pan-PI3K inhibitor that targets all class I PI3K isoforms and is active in both hematologic malignancies and solid tumors. In the animal model, Buparlisib significantly inhibited tumor growth and shows a dose response trend in anti-PD-1 refractory tumor bearing mice. The dose range of Buparlisib is consistent with previous preclinical studies conducted with BKM120 (Buparlisib, AN2025) by Novartis.

With the promising data from the BERIL-1 study, along with this supportive non-clinical work, a Phase III clinical trial is underway to evaluate Buparlisib (AN2025) plus Paclitaxel versus Paclitaxel alone in refractory, recurrent or metastatic HNSCC patients who have progressed after prior platinum-based chemotherapy with or without prior anti-PD1/anti PDL1 antibody treatment (The BURAN Study).

“We are encouraged by the results of animal model study, combined with the phase II data, it supports including anti PD1 exposed patients in our phase III clinical trial. Check point inhibitors are being studies in the first line setting and Buparlisib may fill the second line space in patients who fail treatment,” said Dr. Lars Birgerson, CDO, President and CEO of Adlai Nortye USA Inc.

Carsten Lu, CEO of Adlai Nortye, remarked, “We are firmly committed to bringing Buparlisib to the market for the treatment of HNSCC, to meet the unmet medical need, and to fulfill our mission to transform cancer into a chronic disease condition, even cure the cancer disease.”

About Buparlisib (AN2025）

AN2025 is an oral pan-PI3K inhibitor that targets all class I PI3K isoforms and is active in both hematologic malignancies and solid tumors. It has shown promising efficacy in combination with paclitaxel in HNSCC and received a Fast-Track designation and an approval for initiating the phase III clinical study from FDA.

About Adlai Nortye

Adlai Nortye is a global clinical-stage biopharmaceutical company that is developing differentiated, innovative immuno-oncology medicines. Adlai Nortye focuses on discovering and developing important new treatments for cancer with a mission to improve patient lives by identifying and developing differentiated innovative medicines that help people live better, live longer. Through close collaborations with global partners, Adlai Nortye have successfully positioned itself in the field of immuno-oncology and have several programs ongoing from early pre-clinical to phase III ready. 

For further information, please visit: http://www.adlainortye.com/en.php

View original content:http://www.prnewswire.com/news-releases/adlai-nortyes-buparlisib-an2025-set-to-become-a-potential-treatment-for-anti-pd-1-non-responding-tumor-in-hnscc-300813063.html

MUNICH, March 15, 2019 /PRNewswire/ — Dornier MedTech (Dornier), the global leader in stone management that pioneered Extracorporeal Shockwave Lithotripter (ESWL) technology, today announced that it will launch its new Dornier OptiVision state-of-the-art Next-Generation Digital Image Processing technology for digital radiography at the 34^th Annual EAU Congress in Barcelona, held from 15 to 19 March 2019.

Dornier OptiVision will offer world class digital image processing which allows users to identify and eliminate stones without cumbersome manual post-processing; Dornier OptiVision has been designed to deliver sharp image details and comfortable reading, especially in the field of stone treatment and Endourology.

The software utilizes multi-frequency processing to significantly enhance image quality compared to standard Urology images. Dornier OptiVision will enable its users to strike an optimal balance between low radiation dose and high image quality, serving as a powerful tool in the management, and potential reduction of patient radiation dosage in imaging procedures.

Dornier OptiVision also represents a significant step for the company’s ambitions in two areas:

• Developing the Highly Acclaimed Dornier Delta^® III into a platform for both Stone Treatment and Day-to-Day Endourology procedures
• Extending the suite of SmartLitho™ functionality that allows global ESWL users access to the power of software, big data, and analytics in the field of Urology.

The company’s other developments in SmarthLitho™ functionality will also be showcased at the EAU Congress, featuring in 2 of the 4 poster presentations being made this year from the group.

Georg Frosch, Assistant General Manager Europe North, Middle East & Africa said: “The launch of our Dornier OptiVision technology signifies our commitment to make ESWL relevant for tomorrow’s urologists. OptiVision is another example of our commitment to innovate and create a portfolio of solutions that increase productivity, make diagnosis simpler and create smoother workflows for urologists.”

Previews of the Dornier OptiVision technology will take place at the Dornier MedTech booth (Hall 8, Booth K26).

Ends

About Dornier MedTech

Dornier MedTech is headquartered in Munich, Germany, and is a full subsidiary of Accuron MedTech.

Dornier is a medical device company focused on providing leading technology and improving life by delivering scientifically superior products and solutions to physicians, healthcare providers and research groups involved in urological care.

As pioneers of the lithotripsy and a variety of surgical lasers, Dornier’s 40 years of innovation and service have made it one of the most trusted MedTech companies in the industry.

About Accuron MedTech Group

Accuron MedTech Group is one of the largest medical device companies in Southeast Asia. It is a vertically integrated medical device company and a global medical technology leader with a core focus in urology devices and services.

Headquartered in Singapore, with operations in US, Germany, Spain, France, Italy, China, Malaysia and Japan, the Company serves millions of patients and physicians in about 100 countries worldwide. Accuron MedTech makes strategic investments in disruptive medical technology companies, strengthening its portfolio of healthcare solutions for customers around the world.

Accuron MedTech is an independent division of Accuron Technologies, a wholly-owned subsidiary of Temasek Holdings. For more information on Accuron MedTech, please visit www.accuronmedtech.com.

Logo – https://photos.prnasia.com/prnh/20190315/2403827-1

DALLAS, Texas, March 14, 2019 /PRNewswire/ — Bertolli® Extra Virgin Olive Oil is a healthy part of any diet, but it’s also an essential part of some of today’s most trendy nutrition regimens. From keto to paleo, vegetarian to vegan, extra virgin olive oil is a simple way to provide healthy fats, flavor and antioxidants to any dish.

When incorporating fat into any diet, it’s important to know that not all fats are created equal. Olive oil is high in monounsaturated fats which means rather than clogging your arteries, this type of fat benefits your body in multiple ways — for instance, by providing key nutrients for your cells and balancing cholesterol levels.

Eating the EVOO Way

Mediterranean

One diet that uses olive oil more than most? The Mediterranean diet, named best diet of 2019 by U.S. News and World Report. Inspired by the fresh eating habits of countries surrounding the Mediterranean Sea, this regimen is less a restrictive diet and more of a culinary lifestyle. By focusing on unprocessed foods like fruit, vegetables, nuts, whole grains, olive oil and spices, and bringing in meat, poultry and dairy in moderation, the Mediterranean diet is easy to follow and maintain.

Keto

The high-fat keto diet works by inducing ketosis — a metabolic process that burns the body’s stored fat into fuel — and requires dieters to avoid carbohydrates and sugar. For keto dieters, consuming enough fat is essential to staying healthy and feeling satisfied. A simple way to do that is by relying on extra virgin olive oil. With zero carbs and 100 percent fat, it’s a great way to avoid an excess of saturated fat (from butter, red meat, cream, lard, coconut oil and more) and add a bright, vegetal flavor to an otherwise meat-heavy diet.

Paleo

The paleo diet, or Paleolithic diet — named after the diet of cavemen in the Paleolithic era — is centered around foods that could be hunted and gathered and excludes anything processed or refined. That means no dairy, sweets, processed meats and more. In the absence of butter, canola oil and other refined cooking oils, extra virgin olive oil is an ideal way to cook the lean meats and non-starchy vegetables that comprise the cornerstones of this diet.

Vegetarian

Sticking to a vegetable-centered plan? Olive oil can be used in a million different ways to bring out the sweetness and depth of all kinds of veggies. From sautéing to roasting, braising to grilling, extra virgin olive oil is a healthy way to bring any veggie dish together.

Vegan

Vegans avoid any animal products and byproducts. Luckily, extra virgin olive oil is a simple swap for butter not only in cooking but baking as well. Try it in olive oil cake (the fruitier the extra virgin olive oil, the fruitier the final cake will be!). Cooking, sautéing or frying vegetables in olive oil creates a caramelized, crispy exterior — you’ll never miss the meat.

No matter the diet of choice, using Bertolli Extra Virgin Olive Oil will both enhance the flavors of the cuisine while providing the body with an extra dose of health benefits, from brain fitness to heart health. For recipes and more information follow this link to the Bertolli Essentials website.

About Bertolli

Born in Italy, Bertolli is one of the world’s most popular olive oils. It’s been at the heart of Italian cuisine for 150 years and epitomizes Italians’ famed enjoyment of cooking and of food. At the core of the Bertolli brand is a firm commitment to quality, to the use of natural ingredients and to the tradition of creating excellent and tasty food.  For more information, visit https://essentials.bertolli.com/.  You can find the latest news at Facebook.com/Bertolli and on Twitter @Bertolli, Instagram @Bertolli_US and Pinterest.com/Bertolli.

View original content to download multimedia:http://www.prnewswire.com/news-releases/bertolli-extra-virgin-olive-oil-is-the-must-have-staple-for-every-diet-300812335.html